Format

Send to

Choose Destination
AIDS. 2004 Apr 30;18(7):1074-6.

Renal safety of tenofovir in HIV treatment-experienced patients.

Author information

1
Department of Nephrology, Pitie-Salpêtrière Hospital, Paris, France.

Abstract

The safety of tenovir disoproxil fumarate (TDF) was assessed in two double-blind, placebo-controlled studies. Furthermore, we retrospectively collected 19 cases of TDF-associated tubular dysfunction. The incidence of renal events was similar among the active TDF groups and the placebo group in the two double-blind, placebo-controlled studies. Proximal tubulopathy was diagnosed 6.89 +/- 5.51 months after TDF therapy started. All abnormalities normalized within 4.7 +/- 2.94 weeks after drug discontinuation.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center